Paris, France, May 1, 2017 — Prof. Andrew Coats of Monash and Warwick Universities presented today at a late breaking trials session of the Heart Failure 2017 congress the 18-month and 2-year follow-up results of the AUGMENT-HF trial. AUGMENT-HF is a multicentric randomized clinical study to evaluate the safety and efficacy of Algisyl, an implantable hydrogel for the treatment of Advanced Heart Failure. The results presented in Paris confirmed that the significant clinical benefits observed and published previously in patients treated with Algisyl in comparison to patients treated with optimal medical therapy were sustained throughout the 18- and 24-month marks. Specifically, NYHA function class, quality of life, and patient global assessment remained constant in the Algisyl® treatment arm and the number of heart failure hospitalizations remained lower than in the optimal medical therapy group. The results presented by Prof. Coats underscore the long term benefits of the single implantation procedure of Algisyl®.